Introduction
============

NHL (non-Hodgkin Lymphoma) represents a heterogeneous group of lymphocytic disorders ranging in aggressiveness from very indolent cellular proliferation to highly aggressive and rapidly proliferative processes. Although it is the fifth cause of cancer incidence and mortality in the US, NHL remains poorly understood and is largely incurable.[@b1-cin-2010-281] In clinic, established adverse prognostic factors for NHL include older age at diagnosis, higher tumor stage, poorer performance score, extranodal involvement, above-normal lactate dehydrogenase, and B-symptom presence.[@b2-cin-2010-281],[@b3-cin-2010-281] Recent molecular studies suggest that, beyond clinical and environmental factors, the prognosis of NHL is also affected by genomic variations which can be measured using SNPs (single nucleotide polymorphisms).[@b4-cin-2010-281]--[@b6-cin-2010-281] In this article, when referring to "prognosis", we limit ourselves to overall survival. Disease-free and other types of survival have different patterns and different genomic bases and should be investigated separately.

The ultimate goal of NHL genomic studies is to identify markers that can be used to construct predictive models for prognosis. In this article, we analyze a genetic association study on NHL prognosis. Our particular goal is to identify *gene pathways with significant additional predictive power* beyond clinical factors. More specifically, consider two types of models. The first is constructed using both gene pathways and clinical risk factors, whereas the second is constructed using only clinical risk factors. With a specific pathway, if the predictive power of the first type of model is significantly larger than that of the second type of model, we conclude that this pathway has significant additional predictive power.

Although there are many existing statistical methods for the analysis of genetic association data, they are not directly applicable to our study, as our goal is fundamentally different from that in existing studies. More specifically, many existing methods are single-marker based and consist of the following steps. First, for each SNP, a model (eg, Cox proportional hazards model) with the survival outcome as response and "SNP + clinical risk factors" as covariates is constructed. Second, for each SNP, its estimation significance, measured with the *P*-value from (eg,) the likelihood ratio test, is computed. Third, SNPs with *P*-values below a threshold are declared as significant. These methods analyze one SNP at a time, that is, the marginal effects of SNPs. They are proper for simple Mendelian diseases. Lymphoma is a multiple-factor complex disease, resulting from the interplay of multiple genetic and environmental factors. Single- marker analysis may miss SNPs with weak marginal but strong joint effects. In addition, single-marker analysis cannot effectively incorporate prior biological information of genes, which has been accumulated over time from a large number of independent studies.[@b7-cin-2010-281] Our analysis is pathway-based. Pathway is a way of describing the interplay among genes, where pathways are composed of multiple genes (SNPs) with related biological functions. "Pathway analysis is a promising tool to identify the mechanisms that underlie diseases, adaptive physiological compensatory responses, and new avenues for investigation".[@b8-cin-2010-281] Compared with single marker-based analysis, pathway-based analysis has led to results that are more reproducible and more interpretable.[@b7-cin-2010-281],[@b9-cin-2010-281],[@b10-cin-2010-281] Our pathway analysis approach is also fundamentally different from existing ones. More specifically, many existing pathway analysis methods analyze one SNP at a time and then combine SNP-level analyses to make pathway-level conclusions. Such methods, including the GSEA (gene set enrichment analysis)[@b10-cin-2010-281],[@b11-cin-2010-281] and maxmean approach,[@b12-cin-2010-281] are suitable for answering "which pathways are enriched with SNPs marginally associated with disease". But they cannot quantify the joint effects or coordination of multiple SNPs within the same pathways. In addition, many pathway analysis methods focus on the model estimation aspect as opposed to prediction. To further elaborate, we consider a Cox model for the survival time *T*. This model postulates that *λ*(*t* \| *X*,*Z*) = *λ*~0~(*t*) exp(*αX* + *βZ*), where *λ*(*t* \| *X*,*Z*) is the conditional hazard function, *λ*~0~(*t*) is the unknown baseline hazard, *X* and *Z* are the clinical factors and SNPs respectively, and *α* and *β* are the unknown regression coefficients. It is possible to construct an example where the estimate of *β* is statistically significant and the magnitude of *αX* is much larger than that of *βZ*. Existing methods focus on the significance of model estimation and may conclude the significance of SNPs. However, since the magnitude of *βZ* is relatively small, predictions with and without SNPs may have ignorable differences. That is, adding the SNPs to the model with clinical factors does not significantly improve prediction. Thus, we may conclude the insignificance of SNPs in terms of additional predictive power.

In this article, we study the genomic basis of NHL prognosis. As pathway analysis is conducted, this study may provide additional insights beyond individual-marker based analysis. Unlike in existing studies, we target the predictive power directly. Thus, the models constructed using identified pathways are expected to have better prediction performance than those using pathways identified with alternative approaches.

Methods
=======

Association study of NHL prognosis
----------------------------------

### Study design

We described the patient selection procedure in [Figure 1](#f1-cin-2010-281){ref-type="fig"}. In this study, cases were histologically confirmed, incident NHL patients diagnosed in Connecticut between 1996 and 2000. Subjects were restricted to women who were 21--84 years old at diagnosis, had no previous diagnosis of cancer except non-melanoma skin cancer, and were alive at the time of interview. This study was limited to female patients only, as men and women may have different etiology factors and this restriction was to prevent confounding by gender. Cases were identified through the Yale Comprehensive Cancer Center's Rapid Case Ascertainment Shared Resource (RCA), a component of the Connecticut Tumor Registry (CTR). All licensed hospitals and clinical laboratories in Connecticut are required by public health legislation to report diagnosed cancer cases. Information on cases identified in the field is sent regularly to RCA, where the case information is entered, verified, and screened against the CTR database. 1122 potential cases were identified. Among them, 167 died before they could be interviewed and 123 were excluded because of doctor refusal, previous diagnosis of cancer, or inability to speak English. Out of the 832 eligible cases, 601 completed an in- person interview. Of the 601 cases, 13 could not be identified in the CTR system, and 13 were found to have a history of cancer prior to the diagnosis of NHL, leading to a prognostic cohort of 575 NHL patients. Among the 575 patients, 496 donated either blood or buccal cell samples. All cases were histologically confirmed by two study pathologists and classified into NHL subtypes according to the World Health Organization classification system. Specifically, 155 had diffuse large B-cell lymphoma (DLBCL), 117 had Follicular lymphoma (FL), 57 had chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL), 34 had marginal zone B-cell lymphoma (MZBL), 37 had T/NK-cell lymphoma, and 96 had other subtypes. Vital status was abstracted from the CTR in 2008. Written consents were obtained from all patients. The study was approved by the Human Subjects Research Review Committee at Yale University and the Connecticut Department of Health.

DNA extraction and genotyping was performed at the Core Genotyping Facility of National Cancer Institute.[@b13-cin-2010-281] DNA was extracted from blood clots using the Puregene Autopure DNA extraction kits (Gentra Systems, Minneapolis, MN) and from buccal cell samples using the phenol-chloroform extraction methods.[@b14-cin-2010-281] A total of 1462 tag SNPs from 210 candidate genes related to immune response were genotyped using a custom-designed GoldenGate assay.[@b15-cin-2010-281] The tag SNPs were chosen from the designable set of common SNPs (minor allele frequency \>5%) genotyped in the Caucasian (CEU) population sample of the HapMap Project (Data Release 20/Phase II, NCBI Build 35 assembly, dpSNPb125) using the software Tagzilla.[@b16-cin-2010-281] For each gene, SNPs within the region 20kb 5′ of the ATG-translation initiation codon and 10kb 3′ of the end of the last exon were binned using a binning threshold of *r*^2^ \> 0.80. When there were multiple transcripts available for genes, the primary transcript was assessed. Duplicate samples and replicate samples were genotyped for quality control and blinded to laboratory personnel. The concordance rates were 99%--100% for all assays. We also included 302 SNPs in 143 candidate genes previously genotyped by Taqman assay.[@b17-cin-2010-281] There were a total of 1764 SNPs measured. The list of SNPs and genes profiled is provided in [Appendix 1](#SD1){ref-type="supplementary-material"}.

### Data processing

We removed patients with more than 20% SNPs missing and then removed SNPs with more than 20% measurements missing. The genotyping data was missing for the following reasons: the amount of DNA was too low, samples failed to amplify, samples amplified but their genotype could not be determined due to ambiguous results, or the DNA quality was poor. We then imputed missing SNP measurements.[@b18-cin-2010-281] As shown in [Figure 1](#f1-cin-2010-281){ref-type="fig"}, for DLBCL, 138 patients passed this screening. Among them, 61 died, with survival times ranging from 0.47 to 10.46 years (mean = 4.16 years). For the 77 censored patients, the follow up time ranged from 5.58 to 11.45 years (mean = 9.08 years). 1730 SNPs passed the screening. For FL, 101 patients passed the screening. Among them, 33 died, with survival time ranging from 0.91 to 10.23 years (mean = 4.64 years). For the 68 censored patients, the follow up time ranged from 4.96 to 11.39 years (mean = 8.83 years). 1729 SNPs passed the screening.

The following demographic and clinical factors were also measured: age (rescaled to mean 0 and variance 1 in analysis for better comparability among covariates), education (level 1 = high school or less; level 2 = some college; level 3 = college graduate or more), tumor stage (level 1--4 and unknown), B- symptom presence (no; yes; unknown), and initial treatment (none; radiation only; chemotherapy-based therapy; other). They included all widely accepted prognostic factors.[@b19-cin-2010-281] Summary statistics for the whole cohort and selected subsets were presented in [Table 1](#t1-cin-2010-281){ref-type="table"}.

### Pathway construction

For each gene, we searched KEGG[@b20-cin-2010-281] for available pathway information. For DLBCL, there were 1229 SNPs belonging to 122 KEGG pathways, with pathway sizes ranging from 1 to 240 with median 12. For FL, there were 1228 SNPs belonging to 122 KEGG pathways, with pathway sizes ranging from 1 to 240 with median 12.

Statistical methods
-------------------

Detecting pathways with significant additional predictive power involves comparing models with and without SNPs. When measuring the predictive power, ideally, independent training and testing datasets are needed. As we do not have access to independent data under comparable settings, we use random partition to generate training and testing datasets. The logrank statistic is chosen as the measure of predictive power. [@b21-cin-2010-281] To avoid an extreme partition, multiple partitions are conducted, leading to the distribution of the prediction logrank statistics. Finally, the FDR (false discovery rate) approach is used to control for multiple comparisons.

Algorithm
=========

1.  Data processing. Measurements with severe missingness are removed from analysis. Measurements with light missingness are imputed. In this study, 20% missing rate is used as the cutoff.

2.  Pathway construction using databases such as KEGG. SNPs without pathway information are removed from downstream analysis.

3.  For each pathway

    a.  Compute the prediction index *PI~C~*~+~*~G~*^,^ which measures the combined predictive power of clinical factors and SNPs. Here the subscript "C+G" stands for "clinical + genomic".

    b.  Compute the prediction index *PI~C~*^,^ which measures the predictive power of clinical factors alone. Here the subscript "C" stands for "clinical".

    c.  Compare *PI~C~*~+~*~G~* with *PI~C~*^,^ evaluate the significance of difference, and quantify the additional predictive power provided by SNPs.

4.  Employ the FDR approach.

In the following subsections, we provide detailed descriptions of Steps 3 and 4.

Quantification of additional predictive power of a single pathway
-----------------------------------------------------------------

Consider a pathway with *m* SNPs. Denote *Z* as the length-*m* vector of measurements. Denote *X* as the length-*l* vector of clinical factors. Denote *T* and *C* as the death and censoring time. Under right censoring, one observes (*U* = min(*T*,*C*), Δ = *I*(*T* ≤ *C*), *X*,*Z*. Consider the following Cox proportional hazards models:
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The Cox model has been extensively adopted in survival analysis. It is semiparametric and can be much more flexible than parametric models. A unique advantage of the Cox model is that the profile likelihood function does not involve the baseline hazard. Thus, the estimation only involves maximization over a small number of parametric parameters. Model (M1) consists of both clinical and genomic factors, whereas model (M2) consists of clinical factors only. In "classic" NHL prognosis studies, genomic factors are ignored and (M2) is adopted. In recent genomic studies, both types of risk factors are considered and model (M1) is the preferred model. Statistically speaking, the validity of models depends on the unknown underlying data generating mechanisms. There is a vast amount of research on the statistical properties of Cox models and their estimates, and will not be repeated here. Comparing the predictive power of (M1) versus that of (M2) can reveal the additional predictive power of SNPs.

Assume *n* iid observations (*U~i~*, *δ~i~*, *X~i~*, *Z~i~*), *i* = 1 ... *n*. Denote *r~j~* = {*k: U~k~* ≥ *U~j~*} as the at-risk set at *U~j~*. Under (M1), the log-partial likelihood function is *R~n~*(*α*,*β*) = ∑*^n^~j~*~=1~ *δ* *~j~*{(*α X~j~* + *β Z~j~*) -- log(∑*~k∈r~* exp (*α X~k~* + *β Z~k~*))}. In a similar manner, we can define the log-partial likelihood function *R~n~*(*α*) under (M2).

In association studies, the sizes of some pathways may be comparable to or even larger than the sample sizes. Direct maximization of the likelihood functions may lead to unreliable maximizers. We propose using the ridge penalization to regularize the estimates.[@b22-cin-2010-281] Under (M1), the ridge estimates of *α*,*β* are
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where *λ~n~* is the tuning parameter, and *α~j~*, *β~j~* are the j-th components of *α*,*β*, respectively. We use the R package *penalized* to compute the ridge estimates.

For a specific pathway, its additional predictive power is evaluated as follows:

1.  Randomly partition data into a training set and a testing set with sizes 3:1;

2.  Under (M1), compute the ridge estimate of *α*,*β* using the training set only. *λ~n~* is selected using 3-fold cross validation. For subjects in the testing set, compute the predictive risk scores *α̂X* + *β̂ Z*. Dichotomize the scores at the median and create two risk groups. Compute the logrank statistic that measures the difference of survival between the two groups;

3.  Repeat Step 2, with (M1) replaced by (M2);

4.  Repeat Steps 1--3 B (eg, 200) times;

5.  *PI~C~*~+G~ consists of the B logrank statistics generated under (M1); *PI~C~* consists of the B logrank statistics generated under (M2);

6.  Conduct a paired Wilcoxon test of *PI~C~*~+~*~G~* versus *PI~C~*. The resulted *P*-value quantifies the significance of additional predictive power.

In Step 1, we randomly partition the data into training and testing sets. The specific way of partitioning makes the sizes of the testing set and each piece of the cross validation set equal. In Step 2, we use the ridge approach to estimate the regression coefficients under (M1) and then quantify the combined predictive power of clinical and genomic factors. The logrank statistic has been extensively used as a measure of predictive power.[@b21-cin-2010-281],[@b23-cin-2010-281] The significance of logrank statistics generated in Step 2 can be easily obtained. However, the significance of these logrank statistics does not indicate a significant contribution of the SNPs. It is possible that the significance simply comes from the predictive power of clinical factors. Thus, to discriminate the predictive power of SNPs from that of clinical factors, we compute *PI~C~* in Step 3. In Step 4, instead of a single logrank statistic, we generate its distribution via multiple partitions. By doing so, we can avoid the risk of an extreme partition. In Step 6, if the comparison of *PI~C~*~+G~ versus *PI~C~* yields a significant result, we conclude that SNPs within this pathway have significant additional predictive power.

Representative plots of *PI~C~*~+~*~G~* and *PI~C~* are shown in [Figure 2](#f2-cin-2010-281){ref-type="fig"}. For FL, two pathways are used as examples: the Endometrial cancer pathway which has significant additional predictive power, and the Glycerolipid metabolism pathway which does not. For a better view, only the estimated densities of the logrank statistics are plotted. It is easy to see that, for a predictive pathway, the estimated densities of *PI~C~* ~+\ G~ and *PI~C~* are well separated. However, for a pathway without predictive power, the estimated densities are almost completely overlapped.

Controlling the FDR
-------------------

Denote *N* as the number of pathways, and *p*~1~ ... *p~N~* as the *P*-values generated from the Wilcoxon tests. a) Set the target FDR to *q* = 0.2; b) Order the *P*- values *p*~(1)~ ≤ ... ≤ *p*~(~*~N~* ~)~; c) Let *r* be the largest *i* such that *p*~(~*~i~*~)~ ≤ *i*/*N* × *q*/*c*(*N* ); d) Pathways corresponding to *p*~(1)~ ... *p*~(~*~r~*~)~ are concluded as having significant additional predictive power. Different pathways may share common genes/SNPs. To account for the possible correlations among *P*-values caused by overlapping pathways, we set *c* (*N*) = ∑*~i~*~=1~*^N^*1/*i*.[@b24-cin-2010-281]

Remarks
-------

(M2) is a submodel of (M1). A seemingly natural way of discriminating the two models is to conduct hypothesis testing within the ANOVA framework. However, such an approach still quantifies model estimation as opposed to prediction. When the number of covariates is much smaller than the sample size, estimation can be a reasonable proxy of prediction. Under the present setup, with the number of covariates considerably large, it is not clear how well estimation can represent prediction. Thus, we choose the proposed approach and assess prediction directly.

The proposed approach shares some similarities with but differs significantly from the one in.[@b25-cin-2010-281] In this study, we analyze association data, which is binary and represents two genotypes. In contrast, Ma and Kosorok[@b25-cin-2010-281] analyzes continuous microarray gene expression measurements. We are interested in quantifying the additional predictive power of genomic factors beyond clinical factors, whereas in,[@b25-cin-2010-281] the interest lies in quantifying the absolute predictive power of all factors. More importantly, since we are only interested in generating consistent estimates and using them for predictions, we use the ridge penalization. In contrast, Ma and Kosorok[@b25-cin-2010-281] is interested in variable selection. Thus, the bridge penalization, which is capable of selection but has significantly higher computational cost, is adopted.

We describe the proposed method for data with a censored survival outcome. It can be extended to other types of outcomes. Specifically, with continuous outcomes, the Cox model can be replaced with a linear model and the logrank statistic can be replaced with the mean squared error. With categorical outcomes, generalized linear models and the classification error can be used. Once statistical models and prediction statistics are determined, the proposed method can be applied. In our prognosis models, additive covariate effects are assumed. In principal, more complicated models, for example those including interaction terms, can be adopted. We note that unlike single-marker analysis, the proposed method investigates all SNPs within the same pathways using a single model. Thus, considering complicated models may dramatically increase the number of unknown parameters and reduce power. We use the Wilcoxon test to compare the prediction indexes. This test is nonparametric and relies on weak assumptions. We have experimented with other tests and concluded the same significant pathways.

Results
=======

To better understand NHL prognosis, we first fit Cox proportional hazards models using only the clinical risk factors. Detailed results were presented in [Appendix 2](#SD2){ref-type="supplementary-material"}. The main findings were consistent with the literature.[@b3-cin-2010-281],[@b19-cin-2010-281]

Pathway identification
----------------------

We focused on DLBCL and FL due to a sample size consideration. We also analyzed all subtypes combined to investigate if there are pathways predictive for NHL overall. The identified pathways were shown in [Table 2](#t2-cin-2010-281){ref-type="table"}. We found that incorporating SNPs could increase the predictive power by a considerable amount. Specifically, for DLBCL, *PI~C~*~+~*~G~* for the identified pathways had medians 2.535, 2.220, 2.094, 2.453, and 2.512, respectively. In contrast, *PI~C~* had medians around 0.552; For FL, *PI~C~*~+~*~G~* for the identified pathways had medians 4.320 and 3.532, respectively. In contrast, *PI~C~* s had medians around 1.212; For NHL overall, *PI~C~*~+~*~G~* s for the identified pathways had medians 5.722, 5.314, and 5.441, respectively. In contrast, *PI~C~* s had medians around 4.411.

Biological implications
-----------------------

Given the limited genetic association studies on NHL survival, there are very few reproduced findings for most of the positive SNPs we identified. However, the links between these SNPs and NHL risk by previous etiology studies confirmed their biological significance in lymphomagenesis.

Five metabolic pathways were found to be predictive: selenoamino acid metabolism pathway and glycine, serine and threonine metabolism pathway for DLBCL, cytochrome P450 drug metabolism pathway, other enzymes drug metabolism pathway, and caffeine metabolism pathway for NHL overall. Metabolic pathway enzymes are involved in activation and detoxification of environmental carcinogens as well as drug metabolism, and the related genes may play important roles in the susceptibility to toxic effects of chemicals and may also influence tumor response to drugs used in NHL treatments. Studies have linked the risk of NHL and its subtypes with genetic variations in various metabolic pathways such as BHMT, CBS, SHMT1,[@b26-cin-2010-281] CYP2C9,[@b27-cin-2010-281] CYP2E1,[@b28-cin-2010-281] GSTP1,[@b29-cin-2010-281] GSTT1,[@b29-cin-2010-281]--[@b31-cin-2010-281] NAT1 and NAT2.[@b32-cin-2010-281] Moreover, low expressions of GPX1 are associated with better survival of DLBCL patients,[@b33-cin-2010-281] and genetic variations in CYP2E1, GSTP1, GSTT1 and NAT1 are associated with NHL survival.[@b19-cin-2010-281] In line with the previous studies, our results from this pathway analysis suggested that metabolic pathway genes are one of the most influential ones that affect lymphoma prognosis.

The type II diabetes mellitus pathway and the insulin signaling pathway were found to be predictive for DLBCL survival. With their immune functions altered, people with diabetes are more prone to NHL. A recent meta-analysis of five cohort studies and ten case-controls studies identified an association between diabetes and increased risk of NHL.[@b34-cin-2010-281] Moreover, studies have shown that insulin and IGF-I play a key role in cell proliferation, apoptosis, and metastasis, thus may be actively involved in tumor formation and progression.[@b35-cin-2010-281] Studies have found that SOCS1 mutation is frequent in lymphoma cells, and SOCS3 over-expression is associated with decreased survival of FL patients.[@b36-cin-2010-281] TNF is one of the most noteworthy genes to date, whose variations are reported as NHL risk alleles. Several studies, including a recent pooled-analysis of nine case-control studies by InterLymph Consortium, have reported that mutations in TNF, especially TNF-308G \> A, are associated with NHL risk.[@b5-cin-2010-281],[@b6-cin-2010-281],[@b37-cin-2010-281] Moreover, TNF-308G \> A has been identified as a predictor of survival in DLBCL patients.[@b38-cin-2010-281]

The TGF-beta signaling pathway was found to be predictive for DLBCL survival. TGF-beta, a secreted multifunctional cytokine, is one of the few known classes of proteins that can inhibit cell growth. It normally functions as a tumor suppressor during early stages of tumorigenesis, whereas at later stages the genetic and epigenetic events convert TGF-beta to a tumor promoter aiding in cell growth, invasion and metastasis.[@b39-cin-2010-281] TGF-beta signaling pathway regulates a wide range of cellular processes including proliferation, differentiation, apoptosis, migration and cellular homeostasis. The knowledge of TGF-beta signaling pathway and cancer is evolving. To our knowledge, no SNP of TGF-beta signaling pathway genes except TNF has been associated with prognosis and survival of NHL. However, the high TGF-beta levels were identified as independent predictors of improved outcome in FL patients,[@b40-cin-2010-281] and MYC gene rearrangements were found to be associated with a poor prognosis in DLBCL patients.[@b41-cin-2010-281]

The endometrial cancer pathway was found to be predictive for FL survival. Studies have found that women with a diagnosis history of endometriosis are at an increased risk of NHL.[@b42-cin-2010-281] In addition, there are strong evidences showing that all genes in this pathway play important roles in single or multiple stages of tumor growth and tumor progression. For example, CASP9 encodes a member of caspase family which plays a central role in apoptosis; Mutations, amplification and over-expression of CCND1 alter cell cycle progression; MLH1 is involved in DNA repair and cell cycle; The protein encoded by MYC plays a role in cell cycle progression, apoptosis and cellular transformation; TP53 regulates target genes that induce cell cycle arrest, apoptosis, senescence and DNA repair; and CTNNB1 plays a role in tumor cell metastasis.[@b43-cin-2010-281] Studies have observed associations between genetic variants in CASP9,[@b17-cin-2010-281],[@b44-cin-2010-281] CCND1 and MYC[@b32-cin-2010-281] and risk of NHL overall and different subtypes. TP53 mutations are found to be predictive for poor survival in DLBCL and FL.[@b45-cin-2010-281]

In addition, the melanogenesis pathway was identified as predictive for FL survival. The consistent observation of melanoma and NHL occurring in the same patients, the similar temporal trends of incidences of melanoma and NHL, and the observed association of UV radiation and NHL risk all strongly suggest a linkage between melanogenesis and lymphomagenesis.[@b46-cin-2010-281],[@b47-cin-2010-281]

Alternative analysis
--------------------

We also analyzed the data using the following alternative pathway-based approaches.

### Gene set enrichment analysis

The GSEA is perhaps the most popular pathway analysis method.[@b10-cin-2010-281],[@b11-cin-2010-281] For each SNP, we fit a Cox model with the "clinical factors + SNP" as covariates and used the SNP's standardized regression coefficient as the statistic. The remaining steps followed.[@b10-cin-2010-281] We used the same FDR control as for the proposed approach. For DLBCL, the GSEA identified 53 pathways. The Selenoamino acid metabolism pathway, TGF-beta signaling pathway, and Insulin signaling pathway were identified. For FL, the GSEA identified 56 pathways but had no overlap with the proposed approach. For all subtypes combined, the GSEA identified 54 pathways. The Drug metabolism-cytochrome P450 pathway was identified.

### Maxmean approach

This approach was proposed in.[@b12-cin-2010-281] It shares similar spirits but differs from the GSEA. For DLBCL, FL, and NHL overall, the maxmean approach did not identify any significant pathways.

### Global test

The global test was proposed in.[@b48-cin-2010-281] For DLBCL and FL, this approach did not identify any significant pathway. For NHL overall, 10 pathways were identified. However, there was no overlap with the pathways identified using the proposed approach.

### Remarks

We compared *PI~C~*~+~*~G~* s of pathways identified using the GSEA and global test versus those not identified, and found no significant difference. That is, the pathways identified using those approaches do not have more predictive power than those not identified.

The above analysis showed the dramatic differences between the pathways identified using different approaches. Such differences are reasonable considering that the three alternative approaches focus on the estimation significance as opposed to predictive power. Similar phenomenon has been observed in.[@b25-cin-2010-281] Of note, there are many other alternative approaches. A complete comparison is almost impossible to achieve. Thus, we focused on the above three, which are perhaps more extensively used than other existing approaches.

Discussion
==========

This study may have the following limitations. First, the prognosis study included only female NHL patients. This restriction was to avoid possible confounding by gender. In addition, all patients were recruited in Connecticut, a state in the northeast US. It is not clear whether the results can be generalized to male patients. There is a very small possibility that the results cannot be generalized to patients from other geographic locations. Second, in the profiling, a candidate-gene approach (as opposed to whole genome scan) was adopted. Genes and SNPs profiled were manually selected. With a total of 1764 SNPs (333 genes), this study was not able to provide a full coverage of the genome. Particularly, the SNPs (genes) profiled might not sufficiently cover all pathways involved. A few pathways had a small number of SNPs. Additional whole-genome studies will be needed to identify more NHL susceptibility SNPs. Third, this study was also limited by the availability of data. In this study, patients were recruited in Connecticut during 1996 and 2000. The prognostic cohort analyzed consisted of 346 patients. Larger- scale, more powerful studies will be needed to obtain more conclusive results. Fourth, the reliability of our analysis results might also be limited by the quality of data, including for example the low call rate. Fifth, the pathway information was extracted from KEGG. It has been recognized that our knowledge of the biological functions of genes and their pathway information is still partial. The pathway information might be refined by using more databases such as BioCarta or updated in the future. Last, the results are obtained from the analysis of a single dataset. Independent validation studies, for example in vitro cell culture studies, are needed to further validate the identify pathways and understand their biological mechanisms.

Despite the aforementioned limitations, this study still has considerable merits. Our literature review suggested the scarcity of genetic association studies on NHL prognosis. The research on NHL genomic markers is still in the early exploration, as opposed to the late confirmation, stage. The pathways and SNPs identified in this study may contribute to our understanding of NHL and serve as basis for future confirmation studies.

Conclusion
==========

NHL is largely incurable and its genetic basis is not well understood. This has motivated researchers to search for genetic variants that have additional predictive power beyond clinical and demographic factors. In this study, pathway-based analysis is conducted. For DLBCL, FL and all subtypes combined, we employ a new approach and identify five, two, and three pathways with significant additional predictive power. We find that there are strong evidences of connections between identified pathways, their genes and NHL prognosis. Although some identified genes have been previously discovered, this can be the first time they are identified in the context of pathway analysis. The identified pathways differ from those identified using alternative approaches, and may provide further insights into mechanisms underlying NHL prognosis.

Supplementary Material
======================

###### 

List of SNPs (genes) genotyped.

###### 

Regression analysis using only clinical risk factors.
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###### 

Patient characteristics.

  Variables                           Cohort 1 (n = 496)   Cohort 2 (n = 346)   DLBCL (n = 138)   FL (n = 101)
  -------------------- -------------- -------------------- -------------------- ----------------- --------------
  Age                                 61.62                61.14                59.36             60.02
  Education            Level 1        206                  135                  53                35
                       Level 2        168                  120                  54                36
                       Level 3        122                  91                   31                30
  Tumor stage          Level 1        238                  177                  72                55
                       Level 2        61                   42                   23                12
                       Level 3        28                   23                   9                 10
                       Level 4        158                  98                   31                23
                       Unknown        11                   6                    3                 1
  B-symptom presence   No             71                   51                   28                13
                       Yes            29                   20                   12                4
                       Unknown        396                  275                  98                84
  Initial treatment    None           173                  123                  21                44
                       Radiation      63                   52                   18                19
                       Chemotherapy   253                  167                  99                38
                       Other          7                    4                    0                 0

**Note:** Age: mean; other variables: count.

###### 

Pathways with additional predictive power.

          Pathway                                    Size   *P*-value   Gene
  ------- ------------------------------------------ ------ ----------- ---------------------------------------------
  DLBCL   Selenoamino acid metabolism                4      0.000009    CBS
          Type II diabetes mellitus                  19     0.00012     SOCS1, SOCS2, SOCS3, SOCS4, TNF
          Glycine, serine and threonine metabolism   7      0.00018     BHMT, CBS, SHMT1
          TGF-beta signaling pathway                 13     0.00018     CDKN2A, IFNG, MYC, TGFB1, TGFBR1, TNF
          Insulin signaling pathway                  15     0.0013      SOCS1, SOCS2, SOCS3, SOCS4
  FL      Endometrial cancer                         10     0.00013     CASP9, CCND1, MLH1, MYC, TP53, CTNNB1
          Melanogenesis                              5      0.00002     MC1R, CTNNB1
  All     Drug metabolism---other enzymes            35     0.00024     NAT1, NAT2, XDH
          Drug metabolism---cytochrome P450          7      0.00044     CYP1A2, CYP2C9, CYP2E1, GSTM3, GSTP1, GSTT1
          Caffeine metabolism                        36     0.00056     CYP1A2, NAT1, NAT2, XDH

**Note:** Size: number of SNPs within pathways; *P*-value: unadjusted *P*-values from Wilcoxon tests.
